Cardiorentis competitors

Cardiorentis Competitors include Omeros, CTI BioPharma, Acticor Biotech and Retrophin.
Add company...
Cardiorentis
Cardiorentis
Cardiorentis is a biopharmaceutical company, developing drug therapies for the treatment of acute heart failure and related cardiovascular diseases.
Omeros
Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.
CTI BioPharma
CTI BioPharma
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers.
Acticor Biotech
Acticor Biotech
Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.
Retrophin
Retrophin
Retrophin is a biopharmaceutical company which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
Founding Date
Founding Date
N/A
Founding Date
1994
Founding Date
1992
Founding Date
2013
Founding Date
2011
Type
Type
Private
Type
Public
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
Zug, CH HQ
Locations
Seattle, US HQ
Locations
Seattle, US HQ
Locations
Paris, FR HQ
Locations
San Diego, US HQ
Dublin, IE
New York, US
Cambridge, US
Employees
Employees
N/A
Employees
173
Employees
100
Employees
8
Employees
135
Valuation ($)
Valuation ($)
N/A
Valuation ($)
719.5 m
Valuation ($)
52.6 m
Valuation ($)
N/A
Valuation ($)
878.6 m
Twitter followers
Twitter followers
N/A
Twitter followers
80
Twitter followers
177
Twitter followers
241
Twitter followers
486

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$64.8m (FY, 2017)
Revenue (est.)
$25.1m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$1.1m (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$3.6m (FY, 2017)
Net income
Net income
N/A
Net income
($53.5m) (FY, 2017)
Net income
($45m) (FY, 2017)
Net income
N/A
Net income
($59.7m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 118.5m
Total funding raised
$ 354.8m
Total funding raised
$ 85.1m
Total funding raised
$ 25.6m
Total funding raised
$ 116m
For sources of this data, please see the company profileDownload Excel

View company profiles

Omeros
HQ
Seattle, US
Employees
173

Omeros Corporation is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.

View company
CTI BioPharma
HQ
Seattle, US
Employees
100

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers.

View company
Acticor Biotech
HQ
Paris, FR
Employees
8

Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.

View company
Retrophin
HQ
San Diego, US
Employees
135

Retrophin is a biopharmaceutical company which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.

View company